Tokenized does not mean underwritable.
The next phase of tokenized finance belongs to products that can survive real scrutiny.
What makes a product
underwritable.
These are the questions that separate capital-ready products from ones that stall. Every assessment is built around them.
- 01Structure
What is actually being underwritten?
The asset exposure, wrapper, claim path, token rights, legal form, and economic reality behind the product narrative.
- 02Economics
How does value move through the product?
Yield profile, fee stack, return path, distributions, spread, incentives, and whether the economics reach the holder the way the materials suggest.
- 03Liquidity
How does capital get in and out?
Subscription or minting, redemption mechanics, secondary-market assumptions, NAV, settlement timing, gates, discounts, and practical exit paths.
- 04Operations
Who makes the product work, and what happens if that process fails?
Counterparties, custody, administration, valuation, compliance, reporting, offchain dependencies, and the operational assumptions the product depends on.
- 05Distribution
Where can the product actually be used, bought, held, or integrated?
Qualified buyer pathways, product partnerships, platform integrations, custodians, advisors, ecosystems, jurisdictions, DeFi compatibility, and composability constraints.
- View services/ outcomeCapital readiness.
A product is capital-ready only when its structure, economics, liquidity, operations, and distribution path are clear enough for the capital it is trying to reach.
The same product has to hold up from both sides.
Find the weak points before allocators do.
An independent assessment of the questions serious allocators will raise about structure, economics, liquidity, operations, and distribution.
- A clear picture of where the product is weakest
- The harder questions surfaced before the first serious allocator conversation
- A remediation path showing what to fix, what can remain open, and what should be sequenced first
Know what you are actually looking at.
Independent analysis of tokenized products before the diligence process consumes your team's time or your committee's attention.
- Coverage of structure, economics, liquidity, operations, and distribution
- Sector context and comparable structures so the product is not evaluated in isolation
- The issuer questions to ask before conviction increases or capital is committed
No placement. No success fee. No mandate to sell.
The work is better when the assessor has nothing else for sale.
Inside both issuers and allocators, incentives can quietly shape decisions. Products get pushed toward launch dates. Capital processes move toward allocation targets. The assessment step should sit outside that pressure.
Every engagement has a fixed scope. The questions, deliverables, timeline, and fee are agreed before work begins. There are no distribution mandates, and no revenue tied to whether the product launches, raises, or receives an allocation.
The result is work built to hold up in the room where a view has to be defended: an investment committee pressing on an allocation, a board reviewing a product structure, or a team deciding whether to pause before going to capital.